ArticlePractical radiation oncology
Salvage Stereotactic Body Radiation Therapy for Locally Recurrent Prostate Cancer: Quality-of-Life Outcomes From a Prospective Clinical Trial.
Article in Practical radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03253744 (Phase I Trial of Image Guided Focally Dose Escalated Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I Trial of Image Guided Focally Dose Escalated Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Who cites it
2 citing papers in PubMed.
- Development and validation of a prediction model for moderate-to-severe radiation dermatitis in patients with nasopharyngeal carcinoma: A machine learning study.Asia-Pacific journal of oncology nursing · 2026Article
- Reirradiation of locally recurrent prostate Cancer: a review of prospective evidence and delineation and planning strategies from the reirradiation Collaborative group (ReCOG).Clinical and translational radiation oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeSalvage stereotactic body radiation therapy (SBRT) for intraprostatic recurrence of prostate cancer is under study in early-phase clinical trials. Presently, the impact of this treatment on toxicity and health-related quality of life (HRQOL) is poorly defined. To our knowledge, we present the first report in the literature of HRQOL and psychometric outcomes from a mature, prospective clinical trial. METHODS AND MATERIALS: NCT03253744 was a phase 1 trial of focal salvage SBRT to doses of 40.0 to 42.5 Gy with target volume delineation guided by
resultsSeventeen participants underwent salvage SBRT and were observed for a median of 24 months (min-max: 18-24 months). Toxicity assessment was completed in all participants, and the HRQOL response rate was 91%. Genitourinary (GU) toxicity was more common than gastrointestinal toxicity with a 24-month cumulative incidence of G2+ AEs of 76.5% (95% CI, 44.6%-90.0%) versus 29.4% (95% CI, 4.1%-48.1%) and G3+ AEs of 11.8% (95% CI, 0.0%-25.8%) versus 5.9% (0.0%-16.4%). GU toxicity peaked at 12 to 15 months and was associated most strongly with urethral reirradiation dose. PROMs were concordant with AEs, with significant differences from baseline noted in the American Urologic Association symptom index, EPIC GU irritation, and EPIC GU incontinence scores at 3 to 6 months, 6 to 9 months, and 9 to 18 months, respectively. No significant differences were noted in gastrointestinal PROMs or PROMIS measures.
conclusionsSalvage SBRT has a favorable treatment-related toxicity and HRQOL profile. Primarily, GU toxicities were observed corresponding to decrements in PROMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.